Skip to content
Screener

West Pharmaceutical Services WST Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

AptarGroup logo
AptarGroupATR
$18.52M+449%
AVT
AvantorAVTR
$1.9M-26.9%
DuPont de Nemours, Inc. logo
DuPont de Nemours, Inc.DD
$84M+2,000%
Amcor logo
AmcorAMCR
$6M+500%
Precision Optics Corporation logo
Precision Optics CorporationPOCI
$0-100%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$397K+39,600%

Other financials

Income statement

See full
Revenue$872.3M+13.8%
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$24.7B+44.8%
Enterprise value$24.58B+45.8%
P/E43.7×+8.7×
P/S7.4×+1.7×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000105770-26-000099
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Principal repayments on finance leases(0.7)(0.5)
Excise tax payments(0.8)(4.2)
Dividend payments(31.5)(30.3)
Proceeds from stock-based compensation awards12.46.0
Employee stock purchase plan contributions3.93.6
Shares purchased under share repurchase programs(454.3)(134.0)
Shares repurchased for employee tax withholdings(2.5)(2.5)
Net cash used in financing activities(473.5)(161.9)

Item 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is West Pharmaceutical Services's stock issuance proceeds?
West Pharmaceutical Services (WST) reported stock issuance proceeds of $6.9M in Q2 2026.
How has West Pharmaceutical Services's stock issuance proceeds changed year-over-year?
West Pharmaceutical Services's stock issuance proceeds increased by 97.1% year-over-year, from $3.5M to $6.9M.
What is the long-term trend for West Pharmaceutical Services's stock issuance proceeds?
Over 4 years (2021 to 2025), West Pharmaceutical Services's stock issuance proceeds has grown at a -21.3% compound annual growth rate (CAGR), from $29.4M to $11.3M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Ask your AI about West Pharmaceutical Services's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude